fda semaglutide compounding news Fifth Circuit probes ban on compounded GLP-1s Hims & Hers stock falls

Bartsch, M., Vital, M., Woltemate, S., Bouwman, F

Additional considerations include: Dietary quality changes during weight loss programmes Increased urinary magnesium excretion in poorly controlled diabetes (though GLP-1 therapy typically improves glycaemic control) Concurrent medications that may affect magnesium status, such as proton pump inhibitors or diuretics It is important to note that routine magnesium monitoring is not currently recommended in NICE guidance (NG28) for patients on GLP-1 therapy

Most people lose around 2% of their body weight in the first month, with more significant weight loss occurring over the next 26 months

Therefore, injection site guidance is identical for both

10.1001/jamainternmed.2024.4661 36 KatoS.SatoT.FujitaH.KawataniM.YamadaY

Avoid heavy, greasy foods: rich meals may worsen stomach symptoms